Roche Holding AG EPS - Earnings per Share 2012-2025 | RHHBY
Roche Holding AG annual and quarterly earnings per share history from 2012 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Roche Holding AG EPS for the quarter ending June 30, 2025 was $0.00, a 0% increase year-over-year.
- Roche Holding AG EPS for the twelve months ending June 30, 2025 was $0.00, a 0% increase year-over-year.
- Roche Holding AG 2024 annual EPS was $1.46, a 26.54% decline from 2023.
- Roche Holding AG 2023 annual EPS was $1.99, a 0.99% decline from 2022.
- Roche Holding AG 2022 annual EPS was $2.01, a 9.12% decline from 2021.
| Roche Holding AG Annual EPS | |
|---|---|
| 2024 | $1.46 |
| 2023 | $1.99 |
| 2022 | $2.01 |
| 2021 | $2.22 |
| 2020 | $2.20 |
| 2019 | $1.97 |
| 2018 | $1.56 |
| 2017 | $1.28 |
| 2016 | $1.41 |
| 2015 | $1.34 |
| 2014 | $1.48 |
| 2013 | $0.87 |
| 2012 | $0.75 |
| 2011 | $1.50 |
| Roche Holding AG Quarterly EPS | |
|---|---|
| 2025-06-30 | $0.00 |
| 2024-12-31 | $0.00 |
| 2024-06-30 | $0.00 |
| 2023-12-31 | $0.00 |
| 2023-06-30 | $0.00 |
| 2022-12-31 | $0.00 |
| 2022-06-30 | $0.00 |
| 2021-12-31 | $0.00 |
| 2021-06-30 | $0.00 |
| 2020-12-31 | $0.00 |
| 2020-06-30 | $0.00 |
| 2019-12-31 | $0.00 |
| 2019-06-30 | $0.00 |
| 2018-12-31 | $0.00 |
| 2018-06-30 | $0.00 |
| 2017-12-31 | $0.00 |
| 2017-06-30 | $0.00 |
| 2016-12-31 | $0.00 |
| 2016-06-30 | $0.00 |
| 2015-12-31 | $0.00 |
| 2015-06-30 | $0.00 |
| 2014-12-31 | $0.00 |
| 2014-06-30 | $0.00 |
| 2013-12-31 | $0.00 |
| 2013-06-30 | $0.00 |
| 2012-12-31 | $0.00 |
| 2012-06-30 | $0.00 |
| 2011-12-31 | $0.00 |
| 2011-06-30 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $363.891B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $965.086B | 42.17 |
| Johnson & Johnson (JNJ) | United States | $572.906B | 22.02 |
| AbbVie (ABBV) | United States | $387.093B | 21.90 |
| Novartis AG (NVS) | Switzerland | $325.207B | 17.14 |
| Merck (MRK) | United States | $297.222B | 13.35 |
| Novo Nordisk (NVO) | Denmark | $193.513B | 11.08 |
| Pfizer (PFE) | United States | $150.614B | 8.20 |
| Sanofi (SNY) | France | $115.828B | 10.72 |
| Innoviva (INVA) | United States | $1.613B | 8.08 |